Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Admitted to a hospital with pulmonary symptoms of active COVID-19.~2. Patient (or legally authorized representative) provides informed consent prior to initiation of any study procedures.~3. Patient (or legally authorized representative) understands and agrees to comply with planned study procedures.~4. Male or nonpregnant female adult ≥18 years of age at time of enrollment.~5. Has laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay (serology is not acceptable) in any specimen, as documented by either of the following:~   1. Laboratory confirmed SARS-CoV-2 infection by method as defined above, in sample collected \<72 hours prior to randomization; OR~  2. Laboratory confirmed SARS-CoV-2 infection by method as defined above, in sample collected ≥72 hours prior to randomization, documented inability to obtain a repeat sample (e.g., due to lack of testing supplies, limited testing capacity, results taking \>24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.~6. Has a score of 4 (hospitalized, oxygen by mask or nasal prongs), 5 (hospitalized, noninvasive ventilation or high-flow oxygen), or 6 (hospitalized, intubation and mechanical ventilation) in the ordinal scale.~7. Women of childbearing potential must agree to either abstinence or use at least 1 primary form of contraception not including hormonal contraception from the time of screening through Day 29. (Double-barrier method \[condoms, sponge, diaphragm, with spermicidal jellies, or cream\] is acceptable).~8. Agrees to not participate in another clinical study for the treatment of COVID-19 or SARS-CoV-2 through Day 29. However, Food and Drug Administration (FDA)-approved or under an emergency use authorization antivirus or other drugs may be allowed, and that should be judged by the patient's physician.~Exclusion Criteria:~1. Any condition, including any significant medical or neuropsychiatric condition, including the presence of laboratory abnormalities, which in the judgment of the investigator places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study including, but not limited to:~   1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 × the upper limit of normal (ULN) at screening.~  2. Total bilirubin or alkaline phosphatase level \>3.0 × the ULN at screening.~  3. Platelet count \<100 × 109/L.~2. Extracorporeal membrane oxygenation required at baseline.~3. Stage 3 or end stage renal disease (ESRD) patients with acute renal insufficiency may be considered only after discussion with medical monitor.~4. Is at increased risk for bleeding events (e.g., had recent cerebral hemorrhage, gastrointestinal bleeding, serious trauma, recent surgery, or organ biopsy).~5. Pregnant (patient has a positive pregnancy test result at screening) or breast-feeding.~6. Anticipated discharge from the hospital or transfer to another hospital which is not a study site.~7. Allergy to any study medication or known allergy to nonsteroidal anti-inflammatory drugs, including aspirin.~8. Patient must agree to refrain from taking oral aspirin or any orally administered acetylsalicylic acid medications until PK sampling is completed to be eligible to participate in the PK sub-study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose of Active Drug (Type: EXPERIMENTAL): 80 patients will be randomly assigned to low dose, take active drug BID.
- Low Dose Placebo Control (Type: EXPERIMENTAL): 80 patients will be randomly assigned to Low dose placebo, take the placebo BID.
- High Dose of Active Drug (Type: EXPERIMENTAL): 160 patients will be randomly assigned to high dose, take the active drug BID.
- High Dose Placebo Control (Type: EXPERIMENTAL): 80 will be randomly assigned to high dose placebo, take the placebo BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues